Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ironwood PharmaceuticalsIRWD -1.59%65 Days Sales Outstanding is 88.22 as of Jun. 2026, which is 8% below its 10-year median of 95.39. GuruFocus rates IRWD with a GF Score™ of 65/100 and a GF Value™ of $4.64 (Fairly Valued). The stock has 6 warning signs investors should review. Among 946 Drug Manufacturers companies, Ironwood Pharmaceuticals ranks worse than 65.22% on this metric.
Ironwood Pharmaceuticals (NAS:IRWD) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Ironwood Pharmaceuticals Days Sales Outstanding Related Terms
Ironwood Pharmaceuticals Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Ironwood Pharmaceuticals's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ironwood Pharmaceuticals Days Sales Outstanding Chart
IRWD vs TLRY, AQST, EOLS: Days Sales Outstanding Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ironwood Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ironwood Pharmaceuticals Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ironwood Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Ironwood Pharmaceuticals's Days Sales Outstanding falls into.
Ironwood Pharmaceuticals Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ironwood Pharmaceuticals (IRWD) has a Days Sales Outstanding of 88.22 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Ironwood Pharmaceuticals and its competitors. This is near median its historical median of 95.39. Over the past decade, Ironwood Pharmaceuticals' Days Sales Outstanding has ranged from 79.27 to 112.26. According to the industry distribution chart, Ironwood Pharmaceuticals ranks #617 out of 946 companies in the Drug Manufacturers industry, placing it in the top 65.2%.
Is Ironwood Pharmaceuticals' Days Sales Outstanding too high?
Ironwood Pharmaceuticals' current Days Sales Outstanding of 88.22 is near median its 10-year median of 95.39. Over the past 10 years, this metric has ranged from a low of 79.27 to a high of 112.26. The Drug Manufacturers industry median Days Sales Outstanding is 71.89. Ironwood Pharmaceuticals' value of 88.22 is 22.7% above this industry median. Based on the distribution chart, Ironwood Pharmaceuticals ranks #617 out of 946 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Ironwood Pharmaceuticals has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ironwood Pharmaceuticals' Days Sales Outstanding compare to TLRY and AQST?
According to the Drug Manufacturers industry distribution chart, Ironwood Pharmaceuticals ranks #617 out of 946 companies for Days Sales Outstanding. This places Ironwood Pharmaceuticals in the lower half of its industry. The industry median Days Sales Outstanding is 71.89. Ironwood Pharmaceuticals' value of 88.22 is 22.7% above this benchmark. Historically, Ironwood Pharmaceuticals' own Days Sales Outstanding has ranged from 79.27 to 112.26 over the past decade. While the company's 10-year median is 95.39 vs. the industry median of 71.89, Ironwood Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.89, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ironwood Pharmaceuticals's current Days Sales Outstanding of 88.22 is 22.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Ironwood Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ironwood Pharmaceuticals's current Days Sales Outstanding is 88.22, which is near median its own 10-year median of 95.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ironwood Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ironwood Pharmaceuticals (IRWD) is currently considered Fairly Valued. The stock's GF Value™ is $4.64, compared to a current price of $4.34 — trading 6.6% below its estimated fair value. The current Days Sales Outstanding is 88.22, which is near median its 10-year median of 95.39 and 22.7% above the Drug Manufacturers industry median of 71.89. Ironwood Pharmaceuticals' overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Ironwood Pharmaceuticals (IRWD), the current Days Sales Outstanding is 88.22 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ironwood Pharmaceuticals (IRWD) Overvalued in 2026?
Based on GuruFocus' analysis, Ironwood Pharmaceuticals stock appears to be undervalued.
The current stock price of $4.34 is trading 6.6% below its estimated GF Value™ of $4.64.
GuruFocus considers Ironwood Pharmaceuticals to be Fairly Valued.
Key valuation signals for IRWD:
Days Sales Outstanding: 88.22 (near median its 10-year median of 95.39)
GF Value™: $4.64 vs. price of $4.34 (6.6% below fair value)
Industry Position: 22.7% above the Drug Manufacturers median (#617 of 946)
No single metric tells the full story. See the IRWD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
65GF Score
Get the complete analysis for IRWD
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IRWD has been successfully added to your 
